Quick Facts

• Therapeutic Domain 1: Management of high blood pressure (hypertension).
• Therapeutic Domain 2: Symptom control for certain forms of chest pain (angina pectoris).

Cardifen is a therapeutic option used in the management of specific cardiovascular conditions. It is indicated to address high blood pressure (hypertension), an intervention aimed at supporting the maintenance of healthy blood pressure levels. Controlling this condition may contribute to reducing the likelihood of related serious health events.

The compound is also utilized for the symptom control of certain types of chest pain, known as angina pectoris. This includes the management of chronic stable angina and vasospastic (Prinzmetal's or variant) angina. Its use may help to reduce the frequency of uncomfortable episodes in affected individuals.

This medication is generally considered to be a well-tolerated option for appropriate patients and may be administered alone or in combination with other treatments as determined by a healthcare professional. Comprehensive details regarding its applications are defined within its clinical profile.

Who Can and Cannot Use Cardifen?

Eligibility for Cardifen (Nifedipine) is determined by regulatory agencies and is based on a patient's age, medical history, and specific clinical conditions.

Cardifen is primarily intended for adults (aged 18 and over). Use in children and adolescents is generally not established or not recommended for the labeled indications due to insufficient safety and efficacy data. Older adults require caution and often a lower starting dose.

Contraindications and Restrictions

The medicine is absolutely contraindicated for patients who have experienced:

• Known hypersensitivity to Nifedipine or other dihydropyridine calcium channel blockers.
• Cardiogenic shock or recent acute myocardial infarction.
• Concomitant use with the antibiotic Rifampicin.

Conditional Use

Certain populations must use Cardifen with caution and under close monitoring, as officially documented:

• Hepatic Impairment: Patients with liver function impairment may require a dose adjustment due to slower clearance of the drug.
• Pregnancy and Lactation: Use during pregnancy is generally restricted or contraindicated unless the medical need is compelling. The drug is excreted into breast milk, requiring a risk assessment before use during lactation.

Interactions with other medicines and products

Cardifen (Nifedipine) has officially documented interaction patterns primarily centered on its metabolism through the CYP3A4 enzyme system, as described in regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with potent CYP3A4 inducers, such as Rifampin, is formally contraindicated because it severely reduces the plasma concentration of Cardifen, risking a loss of therapeutic effect. Similarly, the herbal product St. John's Wort and strong CYP3A4-inducing antiepileptic medicines are not recommended. Ingestion of Grapefruit or Grapefruit Juice must be strictly avoided, as it officially leads to a substantial increase in Cardifen systemic exposure (AUC and Cmax).

Pharmacokinetic and Pharmacodynamic Effects

Substances that inhibit CYP3A4 (e.g., Clarithromycin, Itraconazole) may lead to increased systemic exposure of Cardifen. Conversely, Cardifen may also affect other medications; for instance, regulatory documents note that co-administration can elevate the plasma concentrations of Digoxin and the immunosuppressant Tacrolimus. Pharmacodynamically, combining Cardifen with other antihypertensive agents (e.g., beta-blockers) may result in an additive effect and the documented risk of excessive hypotension.

Administration Requirements

Official labeling specifies that sufficient time, at least 36 hours, must be allowed for Cardifen to be washed out of the body prior to surgical procedures involving high-dose Fentanyl anesthesia.

Molecular Target: L-Type Calcium Channel Blockade

Cardifen (Nifedipine) acts by directly binding to and antagonizing the L-type voltage-gated calcium channels (Cav1.2) found primarily on vascular smooth muscle cell membranes. This targeted mechanism inhibits the critical influx of extracellular calcium ions ( Ca^2+) needed for muscle contraction, thus initiating a molecular cascade that promotes relaxation of the arterial walls.

Mechanistic Cascade and Vascular Tone Modulation

The cellular blockade of Ca^2+ entry interferes with the excitation-contraction coupling pathway, specifically preventing the activation of myosin light chain kinase and the subsequent formation of cross-bridges essential for muscle contraction. This effect causes widespread arterial vasodilation, which physiologically leads to a reduction in Systemic Vascular Resistance (SVR) and a decrease in the afterload on the heart.

Selectivity and Constraints of the Mechanism

The drug exhibits high tissue selectivity for the vascular system over the myocardium. The mechanism chiefly modulates blood vessel tone, resulting in limited direct modulation of cardiac contractility. Furthermore, its action is voltage-dependent, meaning it preferentially engages and blocks channels in already contracted, depolarized arteries, concentrating the relaxing effect in depolarized vascular tissue.

Official Administration and Dosing Guidelines

Cardifen, which contains Nifedipine, is strictly for oral administration and is supplied primarily as an Immediate-Release (IR) capsule and an Extended-Release (ER) tablet. The specific dosage form dictates the frequency of use and the necessary handling instructions.

---

Formulation Type	Dosing Schedule (Adult Regimens)	Administration Frequency
Extended-Release (ER)	Starting dose is typically 30 mg or 60 mg once daily. The maintenance range is 30 mg to 90 mg.	Once daily (at consistent 24-hour intervals).
Immediate-Release (IR)	Starting dose is 10 mg three times a day. The maintenance range is 10 mg to 30 mg three to four times a day.	Multiple times per day (e.g., every 8 hours).

---

Procedural and Population Requirements

Administration Constraints: Extended-release tablets must be swallowed whole and must not be chewed, crushed, or divided to maintain their controlled-release mechanism. Furthermore, the consumption of grapefruit or grapefruit juice must be avoided during treatment. Some ER formulations are recommended to be taken on an empty stomach. The dosage is typically adjusted gradually every 7 to 14 days.

Special Populations: Clinical guidelines specify careful monitoring and may necessitate a dose reduction for patients with hepatic impairment. For older adults, a lower maintenance dose may be required, and the use of the immediate-release capsules is generally recommended to be avoided. The safety and efficacy of the ER tablets have not been established in the pediatric population. If a once-daily dose is missed, it should be skipped if the time to the next dose is less than 12 hours.

Research Evidence / Overview of Studies for Cardifen

The research base for Cardifen (Nifedipine) was compiled from clinical evaluations reviewed by health regulators. The available evidence focuses on two key therapeutic areas and consists mainly of Randomized Controlled Trials (RCTs), where patients are randomly assigned to receive the medicine or a comparison treatment, and meta-analyses that combine findings from multiple high-quality studies. This overview describes the research that has been conducted and what remains to be fully explored, without providing medical advice.

---

Evidence for use in Managing High Blood Pressure (Hypertension)

Research has explored the use of the sustained-release (SR) and extended-release (ER) formulations of Cardifen in adults with essential high blood pressure. These studies were conducted to monitor how blood pressure levels evolved in the observed populations and to track potential outcomes related to systemic or functional imbalance, such as changes in systolic and diastolic pressure. Long-term trials were also essential, as researchers studied the occurrence of major cardiovascular events, including stroke and heart attack.

What remains uncertain is fully characterizing the long-term outcomes when treatment is started in very elderly patients. Historically, regulatory and scientific focus shifted primarily to the SR/ER formulations because the immediate-release (IR) formulation was associated with specific patterns of cardiovascular events in some meta-analyses, leaving less recent research on the IR form.

---

Evidence for use in Controlling Chest Pain (Angina Pectoris)

The medicine was evaluated in major long-term trials, including a large-scale RCT, focusing on adults with conditions involving periods of heightened symptoms (chronic stable angina). These studies explored patient-reported outcomes related to physical discomfort and functional measures, such as the ability of participants to exercise. Researchers also tracked the need for surgical procedures and serious events like a heart attack.

The immediate-release formulation was associated with reports of increased chest pain in some meta-analyses, particularly when used alone, resulting in the primary research focus on controlled-release forms for long-term stable management. Evidence is limited regarding the use of the controlled-release formulation in patients with unstable or post-infarction angina, as most research focused on stable patients.

---

Evidence in Special Populations

Cardifen was studied for use in several distinct populations. Research examined older adults with hypertension, and these findings contribute to the broader evidence landscape on how the medicine can be used in this age group, though the results apply only to the populations studied. Specialized studies have also explored the use of Cardifen for hypertensive disorders in pregnancy, such as severe preeclampsia, by focusing on outcomes related to maternal blood pressure control.

Common questions about Cardifen (FAQ)

---

Q: What should I do if I miss a dose of the immediate-release Cardifen?

If you forget to take a dose of the immediate-release formulation, official patient information states to take the dose as soon as it is remembered. However, if it is only a few hours before your next scheduled dose, take only one dose. The patient information emphasizes that two doses should not be taken at once to compensate for a missed dose.

---

Q: Does Cardifen interact with other blood pressure medicines like beta-blockers?

Official regulatory documents indicate that co-administration of Cardifen with beta-blocking agents may result in excessive hypotension (a significant drop in blood pressure) in some individuals. Furthermore, studies and labeling have noted that severe coronary artery disease patients starting nifedipine while on a beta-blocker have rarely experienced increased angina (chest pain) or heart attack.

---

Q: Is Cardifen safe to take while pregnant or breastfeeding?

Official labeling indicates that use during pregnancy is recommended only if the potential benefit is considered to outweigh the potential risk to the fetus, as animal studies have shown adverse effects. The medication is excreted in human breast milk, and official information advises that a medical professional must assess whether the benefit to the mother outweighs the risk to the infant before use during lactation.

---

Q: What is the proper way to take the Cardifen ER tablet?

Official patient instructions specify that the extended-release (ER) tablets must be swallowed whole and should not be crushed, divided, or chewed, as this action can interfere with the drug's release mechanism. In addition, the product information often recommends taking the extended-release tablet on an empty stomach.

---

Q: How soon after starting Cardifen should my blood pressure improve?

The official label notes that for hypertension (high blood pressure), blood pressure levels are expected to decrease as a result of treatment. This improvement may not be felt as a change in symptoms, but it can be monitored by a healthcare provider or a blood pressure device.

---

Q: If I stop taking Cardifen suddenly, are there any withdrawal effects?

Official information warns that the abrupt discontinuation of Cardifen may cause blood pressure to increase. This increase could potentially raise the documented risk for serious cardiovascular events like heart attack or stroke. Therefore, any change in treatment should be guided by a healthcare professional.

---

Cardifen (diltiazem) should be stored securely in the container it was provided in, kept tightly closed, and away from the reach of children.

Storage Guidelines

• Temperature: Store the medication at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Brief excursions are generally permitted between 15 C and 30 C (59 F and 86 F).
• Conditions: Protect the medicine from excessive heat, moisture, and direct light. Do not store it in a bathroom or near a kitchen sink.

Disposal Instructions

To dispose of expired or unused Cardifen, do not flush it down a toilet unless specifically instructed to do so by a pharmacist or FDA guidelines. Instead, safely discard the medication through a local drug take-back program or a medicine disposal location, such as a pharmacy or police station, if one is available. If a take-back program is not accessible, you may mix the drug with an unpalatable substance (like dirt or used coffee grounds), place the mixture in a sealed bag, and dispose of it in household trash. Always scratch out personal information on the prescription label before disposal.